Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis



Recruitment Status:  recruiting as of August 2020.


Estimated Completion Date: July 2021


Sponsors and Collaborators: CSL Behring

Information provided by (Responsible Party): CSL Behring

Brief Summary: Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. CSL324 is a novel, recombinant therapy that may treat diseases caused by increased numbers of neutrophils at sites of inflammation.

Please link complete details

Locations: Australia

Contact:  Trial Register Coordinator, 610-878-4000,


© 2021 by HS Connect, LLC  |  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579